Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionCandriam Luxembourg S.C.A.
Latest Disclosed Ownership224,330 shares
Latest Disclosed Value $ 74,224,067
Candriam Luxembourg S.C.A. ownership in DUL / Alnylam Pharmaceuticals, Inc.

On April 30, 2026 - Candriam Luxembourg S.C.A. filed a 13F-HR form disclosing ownership of 224,330 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $64,091,081 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on April 30, 2026 disclosing 224,330 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $58,437,965 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-30 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 224,330 0 0.00 74,224 -16.80 0.3856
2026-04-30 2025-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 224,330 11,914 5.61 89,209 -7.90 0.4449
2026-02-13 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 224,330 11,914 89,209 0.4442
2025-11-06 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 212,416 -25,668 -10.78 96,862 24.76 0.5071
2025-08-08 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 238,084 -11,835 -4.74 77,640 15.05 0.4477
2025-05-14 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 249,919 -32,488 -11.50 67,483 1.55 0.4227
2025-02-07 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 282,407 -69,261 -19.69 66,453 -31.29 0.3827
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 351,668 440 0.13 96,715 13.32 0.5558
2024-08-05 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 351,228 34,330 10.83 85,344 80.20 0.5173
2024-05-06 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 316,898 66,514 26.56 47,360 -1.19 0.3029
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 250,384 -78,510 -23.87 47,928 -17.72 0.3308
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 328,894 10,000 3.14 58,247 -3.84 0.4128
2023-08-08 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 318,894 -9,397 -2.86 60,571 0.07 0.4377
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 328,291 7,796 2.43 60,530 -20.52 0.4198
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 320,495 -32,553 -9.22 76,162 7.77 0.5138
2022-11-10 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 353,048 9,835 2.87 70,670 41.18 0.4979
2022-08-03 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 343,213 39,560 13.03 50,055 0.96 0.4122
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 303,653 63,082 26.22 49,581 21.53 0.3374
2022-02-10 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 240,571 107,492 80.77 40,796 62.37 0.2604
2021-11-09 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 133,079 -41,743 -23.88 25,126 -15.22 0.1708
2021-07-20 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 174,822 12,264 7.54 29,636 46.03 0.2029
2021-04-29 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 162,558 0 0.00 20,295 -3.95 0.1689
2021-01-22 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 162,558 -5,042 -3.01 21,129 -13.41 0.1672
2020-10-19 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 167,600 0 0.00 24,402 -1.70 0.2292
2020-07-23 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 167,600 -23,132 -12.13 24,824 15.61 0.2620
2020-05-26 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 190,732 0 0.00 21,473 -2.25 0.2380
2020-02-05 2019-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 190,732 659 0.35 21,967 43.71 0.2354
2020-01-21 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 190,732 659 22 235,950.2360
2020-02-05 2019-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 190,073 -191,651 -50.21 15,286 -44.57 0.2026
2019-10-21 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 190,073 -191,651 15 188,513.2588
2019-08-01 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 381,724 97,023 34.08 27,576 3.65 0.3439
2019-05-02 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 284,701 0 0.00 26,606 28.18 0.3404
2019-02-14 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 284,701 53,491 23.14 20,757 2.58 0.3190
2018-11-07 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 231,210 112,500 94.77 20,235 73.07 0.2690
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 118,710 23,500 24.68 11,692 3.10 0.1850
2018-05-09 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 95,210 102 0.11 11,340 -6.15 0.1934
2018-02-07 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 95,108 -24,892 -20.74 12,083 -14.30 0.2090
2017-11-03 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 120,000 36,000 42.86 14,099 110.43 0.2463
2017-07-31 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 84,000 17,000 25.37 6,700 95.11 0.1259
2017-04-21 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 67,000 7,000 11.67 3,434 52.89 0.0665
2017-02-01 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,000 0 0.00 2,246 -44.78 0.0515
2016-11-15 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 60,000 -13,000 -17.81 4,067 0.39 0.0978
2016-07-26 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 73,000 12,000 19.67 4,051 6.38 0.1053
2016-04-27 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 61,000 4,000 7.02 3,808 -29.03 0.0952
2016-01-25 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 57,000 -5,400 -8.65 5,366 7.00 0.1436
2015-10-19 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 62,400 -26,600 -29.89 5,015 -52.99 0.1231
2015-07-29 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 89,000 62,000 229.63 10,668 278.30 0.2220
2015-05-28 2015-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 27,000 -6,000 -18.18 2,820 -11.90 0.0568
2015-04-27 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,000 2,819
2015-05-28 2014-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 33,000 33,000 3,201 0.0669
2015-03-26 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 33,000 33,000 3,201 0.0648
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.